ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Achillion Pharmaceuticals, Inc." (ACHN) Report Updated: Sep 22, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Achillion Pharmaceuticals, Inc." (ACHN)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: MDVN, CBMG, ENTA, RGEN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Achillion Pharmaceuticals, Inc."© quotemedia

Company Profile

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C infection (HCV); and the development of antibacterials for the treatment of resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-1625, a NS3 protease inhibitor that is in Phase IIa clinical trials; ACH-2684, a NS3 protease inhibitor, which is in Phase I clinical trials; ACH-2928, a NS5A inhibitor that is in Phase I clinical trials; and ACH-3102, a NS5A inhibitor, which is in Phase I clinical trials. Its pipeline of antibacterial product candidates also includes ACH-702 for the treatment of dermatologic and ophthalmic infections; and ACH-2881 for the treatment of resistant bacterial infections, including methicillin-resistant staphylococcus aureus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Recent News: "Achillion Pharmaceuticals, Inc."